FDA recommends against using Exparel as regional nerve block


eMediNexus    25 February 2018

The US Food and Drug Administrations (FDAs) Anesthetic and Analgesic Drug Products Advisory Committee has voted 6 to 4 against recommending bupivacaine liposomal injectable suspension (Exparel, Pacira Pharmaceuticals Inc) as a nerve block to treat regional postsurgical pain.

To comment on this article,
create a free account.

Sign Up to instantly get access to 10000+ Articles & 1000+ Cases

Already registered?

Login Now

Most Popular Articles

News and Updates

eMediNexus provides latest updates on medical news, medical case studies from India. In-depth medical case studies and research designed for doctors and healthcare professionals.